If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
590.00    2.00 (0.34%)
Bid:
586.00
Ask:
588.00
Spread: 2.00 (0.341%)
Market Cap: £514.04m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Annual Trading Update

8 Oct 2009 07:00

RNS Number : 4270A
Victrex PLC
08 October 2009
 



Thursday 8 October 2009

Victrex plc

Annual Trading Update

Victrex will announce its results for the year ended 30 September 2009 on Tuesday 8 December 2009. Today, the Company announces its regular annual trading update. 

Invibio

Invibio®, our biomaterials division, had an excellent year with revenue of approximately £34.1m, an increase of 37% over the previous year (£24.9m). At £16.5m, second half revenue was down 6% on the very strong first half (£17.6m) principally as a result of inventory rationalisation at certain customers.

 

Group sales volume

Encouragingly, monthly volumes have shown continued improvement throughout the second half due to increased Victrex Polymer Solutions sales. Following the low point of 88 tonnes in March, as previously announced, Group volume recovered to 110 tonnes in April, with a further increase to 142 tonnes in July. This level was sustained in August with a further increase to approximately 155 tonnes in September. Group sales volume for the year is therefore expected to be approximately 1,545 tonnes.

As a result of the sales volume achieved in the fourth quarter, whave increased polymer production levels and have recommenced monomer production.

Outlook

Overall, we expect profits for 2009 to be in line with market expectations.

Invibio continues to show strong sales performance and development potential. Accordingly, we expect further revenue growth in 2010.

While it is still too early to judge the extent to which the recovery in Victrex Polymer Solutions sales volume in the second half of 2009 is due to restocking or a higher level of sustainable demand, it represents a positive trend. However2010 sales volume will be highly dependent on the extent to which this recovery is sustained.

-Ends-

Enquiries

Victrex plc

Mike Peacock, Finance Director 01253 897700 

Hogarth Partnership Limited

Nick Denton / Barnaby Fry 0207 357 9477

Victrex plc is an innovative world leader in high performance materials through the manufacture of VICTREX® PEEK™ polymer, a high performance, easy to process thermoplastic.

With over 30 years of experience, Victrex is a global manufacturer of innovative, high performance thermoplastic polymers. The Victrex Polymer Solutions Division ('VPS') is responsible for polymer business in our major industrial markets including transport, energy and electronics. The Biomaterials Solutions Division ('Invibio') provides specialist solutions for medical device manufacturers.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTCKOKQABDDQKK
Date   Source Headline
8th Jul 20253:33 pmRNSDirector/PDMR Shareholding
8th Jul 20257:00 amRNSDirectorate change: CEO succession
8th Jul 20257:00 amRNSQ3 Trading Update
30th Jun 20251:38 pmRNSTotal Voting Rights
30th Jun 20259:13 amRNSDirector Declaration
18th Jun 20257:00 amRNSAppointment of Joint Corporate Broker
3rd Jun 20251:56 pmRNSHolding(s) in Company
2nd Jun 202511:34 amRNSBlock listing Interim Review
2nd Jun 202510:25 amRNSHolding(s) in Company
30th May 20259:50 amRNSTotal Voting Rights
27th May 202512:40 pmRNSHolding(s) in Company
13th May 20253:30 pmRNSDirector/PDMR Shareholding
12th May 20257:00 amRNSVictrex plc – Interim Results 2025
7th May 20257:00 amRNS‘Magma’ advances via TechnipFMC award
30th Apr 202511:00 amRNSTotal Voting Rights
31st Mar 20259:17 amRNSTotal Voting Rights
21st Mar 202510:34 amRNSDirector/PDMR Shareholding
28th Feb 20259:55 amRNSTotal Voting Rights
19th Feb 20259:00 amRNSAdditional Listing
7th Feb 20251:54 pmRNSResult of AGM
7th Feb 20257:00 amRNSAGM and Trading Update
31st Jan 20259:17 amRNSTotal Voting Rights
21st Jan 20251:56 pmRNSHolding(s) in Company
6th Jan 20251:00 pmRNSAnnual Financial Report
31st Dec 20249:00 amRNSTotal Voting Rights
16th Dec 20248:52 amRNSDirector/PDMR Shareholding
11th Dec 20243:07 pmRNSDirector/PDMR Shareholding
10th Dec 202411:46 amRNSDirector/PDMR Shareholding
10th Dec 20249:28 amRNSHolding(s) in Company
3rd Dec 202410:58 amRNSDirector/PDMR Shareholding
3rd Dec 20247:00 amRNSVictrex plc - Preliminary Results 2024
2nd Dec 20249:38 amRNSBlock listing Interim Review
29th Nov 20249:07 amRNSTotal Voting Rights
14th Nov 20249:31 amRNSHolding(s) in Company
31st Oct 202412:25 pmRNSTotal Voting Rights
14th Oct 20243:09 pmRNSHolding(s) in Company
30th Sep 20241:44 pmRNSTotal Voting Rights
27th Sep 20249:22 amRNSHolding(s) in Company
24th Sep 202411:24 amRNSDirector/PDMR Shareholding
17th Sep 20242:00 pmRNSUS FDA approval: Total Knee Study
12th Sep 202411:18 amRNSDirector/PDMR Shareholding
3rd Sep 20244:20 pmRNSHolding(s) in Company
30th Aug 20243:44 pmRNSDirector/PDMR Shareholding
30th Aug 20249:16 amRNSTotal Voting Rights
23rd Aug 20243:18 pmRNSHolding(s) in Company
9th Aug 202410:08 amRNSHolding(s) in Company
5th Aug 20241:56 pmRNSDirector/PDMR Shareholding
2nd Aug 202411:51 amRNSDirector/PDMR Shareholding
1st Aug 20241:20 pmRNSDirector/PDMR Shareholding
31st Jul 202412:20 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.